GWP
NTLA icon

Gen-Wealth Partners’s Intellia Therapeutics NTLA Stock Holding History

Gen-Wealth Partners’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04M Buy
61,343
+14,167
+30% +$198K 0.29% 78
2026
Q1 		$605K Buy
47,176
+13,861
+42% +$177K 0.19% 110
2025
Q4 		$299K Buy
33,315
+28,012
+528% +$386K 0.1% 218
2025
Q3 		$91.6K Buy
5,303
+5,262
+12,834% +$64.8K 0.03% 330
2025
Q2 		$385 Hold
41
– – ﹤0.01% 618
2025
Q1 		$292 Hold
41
– – ﹤0.01% 599
2024
Q4 		$478 Hold
41
– – ﹤0.01% 622
2024
Q3 		$588 Hold
41
– – ﹤0.01% 631
2024
Q2 		$918 Hold
41
– – ﹤0.01% 601
2024
Q1 		$1.13K Buy
+41
New +$1.14K ﹤0.01% 580

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Gen-Wealth Partners's NTLA Position: Q2 2026 in Review

Gen-Wealth Partners increased its Intellia Therapeutics (NTLA) stake by 30% in Q2 2026, buying an estimated $198K and bringing the position to 61,343 shares worth $1.04M. The position accounts for 0.29% of the portfolio, ranked #78.

Gen-Wealth Partners first reported a position in NTLA in Q1 2024 and has held it in 10 quarters since. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Gen-Wealth Partners held 61,343 shares of Intellia Therapeutics worth $1.04M as of Q2 2026.
  • Gen-Wealth Partners bought 14,167 Intellia Therapeutics shares in Q2 2026, an estimated $198K.
  • Intellia Therapeutics made up 0.29% of Gen-Wealth Partners's portfolio in Q2 2026, its #78 holding.
  • Gen-Wealth Partners first reported a position in Intellia Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Gen-Wealth Partners's 13F filing for Q2 2026, filed 10 Aug 2026.